Show simple item record

dc.contributor.authorStöhr, Stefanie
dc.contributor.authorCosta, Rui
dc.contributor.authorSandmann, Lisa
dc.contributor.authorWesthaus, Sandra
dc.contributor.authorPfaender, Stephanie
dc.contributor.authorAnggakusuma
dc.contributor.authorDazert, Eva
dc.contributor.authorMeuleman, Philip
dc.contributor.authorVondran, Florian W R
dc.contributor.authorManns, Michael P
dc.contributor.authorSteinmann, Eike
dc.contributor.authorvon Hahn, Thomas
dc.contributor.authorCiesek, Sandra
dc.date.accessioned2016-01-05T13:52:18Zen
dc.date.available2016-01-05T13:52:18Zen
dc.date.issued2015-08-14en
dc.identifier.citationHost cell mTORC1 is required for HCV RNA replication. 2015: Guten
dc.identifier.issn1468-3288en
dc.identifier.pmid26276683en
dc.identifier.doi10.1136/gutjnl-2014-308971en
dc.identifier.urihttp://hdl.handle.net/10033/592833en
dc.description.abstractChronically HCV-infected orthotopic liver transplantation (OLT) recipients appear to have improved outcomes when their immunosuppressive regimen includes a mammalian target of rapamycin (mTOR) inhibitor. The mechanism underlying this observation is unknown.
dc.languageENGen
dc.titleHost cell mTORC1 is required for HCV RNA replication.en
dc.typeArticleen
dc.contributor.departmentTWINCORE, Centre for Experimental and Clinical Infection Research; a joint venture between the Medical School Hannover (MHH) and the Helmholtz Centre for Infection Research (HZI), Hannover, Germany.en
dc.identifier.journalGuten
refterms.dateFOA2018-06-13T00:49:47Z
html.description.abstractChronically HCV-infected orthotopic liver transplantation (OLT) recipients appear to have improved outcomes when their immunosuppressive regimen includes a mammalian target of rapamycin (mTOR) inhibitor. The mechanism underlying this observation is unknown.


Files in this item

Thumbnail
Name:
Stöhr et al.pdf
Size:
1.623Mb
Format:
PDF
Description:
Open Access publication

This item appears in the following Collection(s)

Show simple item record